OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
M-CHAI$19.3060

Mahachai Hospital PCL

Healthcare Facilities & ServicesVerified

Mahachai Hospital PCL has a price-to-book ratio of 1.38 and a debt-to-equity ratio of 2.93, indicating a leveraged capital structure with limited liquidity given its current ratio of 0.5. The company's price-to-earnings ratio of 20.21 suggests a moderate valuation relative to earnings, while its enterprise value to EBITDA of 20.92 indicates a relatively high valuation compared to operating performance. The company's return on equity of 6.84% is below the typical benchmark for healthcare providers, and its return on assets of 1.38% is significantly lower than the industry median, suggesting inefficiencies in asset utilization and profitability. The gross profit margin of 19.1% and operating margin of 7.1% are in line with the industry, but the net profit margin of 2.3% is below the median, indicating higher-than-average operating costs or expenses. Mahachai Hospital PCL operates through multiple subsidiaries and hospital brands, including Mahachai 2, Mahachai Petcharat, and Med park, with no disclosed revenue concentration by segment or geography. The company's operations are primarily concentrated in Thailand, with no material international revenue disclosed. The company's revenue for the latest period was THB 6.53 billion, with a year-over-year growth rate of 17.3% and a projected growth rate of 10.2% for the next fiscal year. The operating cash flow of THB 1.26 billion and free cash flow of THB 588 million indicate positive cash generation, but the capital expenditure of THB -204 million suggests ongoing investment in facilities or equipment. The company faces medium liquidity risk due to its low current ratio and high debt levels, with a risk score of medium for liquidity and low for dilution. The risk assessment highlights a key flag of negative net cash after subtracting total debt, which could limit the company's ability to fund operations or growth without external financing. Recent events include a market data ESG controversies score of 100.0, indicating no material ESG controversies, and a governance pillar score of 12.9, which is below the industry median. The company's social pillar score of 79.3 is in line with the industry, suggesting a moderate level of social responsibility.

30-day price · M-CHAI+1.40 (+7.7%)
Low$18.00High$20.00Close$19.70As of15 May, 00:00 UTC
Profile
CompanyMahachai Hospital PCL
TickerM-CHAI.BK
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Mahachai Hospital PCL operates a network of private hospitals and clinics in Thailand, providing a range of medical services including cardiology, gastroenterology, oncology, and health check-ups.

Classification. Mahachai Hospital PCL is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92.

Mahachai Hospital PCL has a price-to-book ratio of 1.38 and a debt-to-equity ratio of 2.93, indicating a leveraged capital structure with limited liquidity given its current ratio of 0.5. The company's price-to-earnings ratio of 20.21 suggests a moderate valuation relative to earnings, while its enterprise value to EBITDA of 20.92 indicates a relatively high valuation compared to operating performance. The company's return on equity of 6.84% is below the typical benchmark for healthcare providers, and its return on assets of 1.38% is significantly lower than the industry median, suggesting inefficiencies in asset utilization and profitability. The gross profit margin of 19.1% and operating margin of 7.1% are in line with the industry, but the net profit margin of 2.3% is below the median, indicating higher-than-average operating costs or expenses. Mahachai Hospital PCL operates through multiple subsidiaries and hospital brands, including Mahachai 2, Mahachai Petcharat, and Med park, with no disclosed revenue concentration by segment or geography. The company's operations are primarily concentrated in Thailand, with no material international revenue disclosed. The company's revenue for the latest period was THB 6.53 billion, with a year-over-year growth rate of 17.3% and a projected growth rate of 10.2% for the next fiscal year. The operating cash flow of THB 1.26 billion and free cash flow of THB 588 million indicate positive cash generation, but the capital expenditure of THB -204 million suggests ongoing investment in facilities or equipment. The company faces medium liquidity risk due to its low current ratio and high debt levels, with a risk score of medium for liquidity and low for dilution. The risk assessment highlights a key flag of negative net cash after subtracting total debt, which could limit the company's ability to fund operations or growth without external financing. Recent events include a market data ESG controversies score of 100.0, indicating no material ESG controversies, and a governance pillar score of 12.9, which is below the industry median. The company's social pillar score of 79.3 is in line with the industry, suggesting a moderate level of social responsibility.
Key takeaways
  • Mahachai Hospital PCL is a leveraged healthcare provider with a price-to-book ratio of 1.38 and a debt-to-equity ratio of 2.93.
  • The company's return on equity of 6.84% is below the industry median, and its return on assets of 1.38% is significantly lower than the median.
  • The company's operations are primarily concentrated in Thailand, with no material international revenue disclosed.
  • The company's revenue is projected to grow by 10.2% in the next fiscal year, with a year-over-year growth rate of 17.3%.
  • The company faces medium liquidity risk due to its low current ratio and high debt levels.
  • The company has a market data ESG controversies score of 100.0, indicating no material ESG controversies.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyTHB
Revenue$6.53B
Gross profit$1.25B
Operating income$460.7M
Net income$152.8M
R&D
SG&A
D&A
SBC
Operating cash flow$1.26B
CapEx-$203.8M
Free cash flow$588.1M
Total assets$11.06B
Total liabilities$8.83B
Total equity$2.23B
Cash & equivalents$791.0k
Long-term debt$6.55B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price$19.30
Market cap$3.09B
Enterprise value$9.64B
P/E20.2
Reported non-GAAP P/E
EV/Revenue1.5
EV/Op income20.9
EV/OCF7.7
P/B1.4
P/Tangible book1.4
Tangible book$2.23B
Net cash-$6.55B
Current ratio0.5
Debt/Equity2.9
ROA1.4%
ROE6.8%
Cash conversion8.2%
CapEx/Revenue-3.1%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
MetricM-CHAIActivity
Op margin7.1%18.2% medp25 18.2% · p75 24.6%bottom quartile
Net margin2.3%14.7% medp25 11.7% · p75 28.1%bottom quartile
Gross margin19.1%19.7% medp25 19.7% · p75 39.8%bottom quartile
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue-3.1%4.9% medp25 4.2% · p75 6.3%bottom quartile
Debt / equity293.0%71.3% medp25 19.0% · p75 91.7%top quartile
Observations
IR observations
Last actual EPS0.35 THB
Last actual revenue1,170,302,000 THB
market data ESG controversies score100.0
market data ESG governance pillar12.9
market data ESG social pillar79.3
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 09:24 UTC#dc47395f
Market quoteclose THB 19.30 · shares 0.16B diluted
no public URL
2026-05-10 09:24 UTC#78a4bfd4
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 09:27 UTCJob: 2382f4b9